Introduction: Moyamoya disease (MMD) is a vascular disease with significant risk of mortality due to ischemia or hemorrhage in the brain. The goal of the study was to explore three-dimensional arterial spin labeling (3D-ASL) to improve evaluation of cerebral hemodynamics in patients with MMD. Methods: Our study included 54 cases of ischemic MMD and 42 cases of hemorrhagic MMD. Dynamic susceptibility contrast-enhanced perfusion-weighted imaging (DSC-PWI) and 3D-ASL were performed at 3.0 T. Based on these scans, cerebral blood flow (CBF), mean transit time (MTT), and time to peak (TTP) were calculated and compared between patients with different disease subtypes. Receiver operating characteristics analysis was used to assess the diagnostic sensitivity and specificity of different imaging procedures and parameters. Results: Our data suggested that CBF in the lesion area was more severely reduced in patients with hemorrhagic MMD than in those with ischemic MMD. The CBF parameter in 3D-ASL diagnosed hemorrhagic and ischemic MMD with a significant sensitivity and specificity of 80.59% and 57.41%, respectively, with an area under the curve (AUC) of 0.75. We also found that the relative CBF of 3D-ASL was more pronounced decreased and the relative MTT and TTP of DSC-PWI were significantly increased in patients with hemorrhagic MMD than those with ischemic MMD. Specificity and sensitivity and AUC of 3D-ASL were better than the comparison of absolute values from DSC-PWI scans. Conclusion: Our study indicated that 3D-ASL is powerful in differentiating patients with cerebral ischemic or hemorrhagic MMD, providing another diagnostic tool that could potentially improve precision medicine to monitoring MMD patients.

Journal Section:
Original Paper
Keywords:
Moyamoya disease, Dynamic susceptibility contrast-enhanced perfusion-weighted imaging, Arterial spin labeling
1.
Wouters A, Smets I, Van den Noortgate W, Steinberg GK, Lemmens R. Cerebrovascular events after surgery versus conservative therapy for moyamoya disease: a meta-analysis. Acta Neurol Belg. 2019;119(3):305–13.
https://doi.org/10.1007/s13760-019-01165-9
2.
Hirano Y, Miyawaki S, Imai H, Hongo H, Ohara K, Dofuku S, et al. Association between the onset pattern of adult moyamoya disease and risk factors for stroke. Stroke. 2020;51(10):3124–8.
https://doi.org/10.1161/STROKEAHA.120.030653
3.
Jo K-I, Kim MS, Yeon JY, Kim J-S, Hong S-C. Recurrent bleeding in hemorrhagic moyamoya disease: prognostic implications of the perfusion status. J Korean Neurosurg Soc. 2016;59(2):117–21.
https://doi.org/10.3340/jkns.2016.59.2.117
4.
Takahashi JC, Funaki T, Houkin K, Kuroda S, Fujimura M, Tomata Y, et al. Impact of cortical hemodynamic failure on both subsequent hemorrhagic stroke and effect of bypass surgery in hemorrhagic moyamoya disease: a supplementary analysis of the Japan adult moyamoya trial. J Neurosurg. 2020;134(3):940–5.
https://doi.org/10.3171/2020.1.JNS192392
5.
Hishikawa T, Tokunaga K, Sugiu K, Date I. Clinical and radiographic features of moyamoya disease in patients with both cerebral ischaemia and haemorrhage. Br J Neurosurg. 2013;27(2):198–201.
https://doi.org/10.3109/02688697.2012.717983
6.
Shi Z, Ma G, Zhang D. Haemodynamic analysis of adult patients with moyamoya disease: ct perfusion and dsa gradings. Stroke Vasc Neurol. 2021;6(1):41–7.
https://doi.org/10.1136/svn-2019-000317
7.
D’Amico A, Ugga L, Cocozza S, Giorgio SMA, Cicala D, Santoro C, et al. Multimodal evaluation of the cerebrovascular reserve in neurofibromatosis type 1 patients with moyamoya syndrome. Neurol Sci. 2021;42(2):655–63.
https://doi.org/10.1007/s10072-020-04574-4
8.
Mihara F, Kuwabara Y, Yoshiura T, Tanaka A, Kaneko K, Sasaki M, et al. Semi-quantitative cbf and cbf ratios obtained using perfusion-weighted mr imaging. Neuroreport. 2003;14(5):725–7.
https://doi.org/10.1097/00001756-200304150-00013
9.
Soldozy S, Galindo J, Snyder H, Ali Y, Norat P, Yağmurlu K, et al. Clinical utility of arterial spin labeling imaging in disorders of the nervous system. Neurosurg Focus. 2019;47(6):E5.
https://doi.org/10.3171/2019.9.FOCUS19567
10.
Meng R, Asmaro K, Meng L, Liu Y, Ma C, Xi C, et al. Upper limb ischemic preconditioning prevents recurrent stroke in intracranial arterial stenosis. Neurology. 2012;79(18):1853–61.
https://doi.org/10.1212/WNL.0b013e318271f76a
11.
Zaharchuk G, Do HM, Marks MP, Rosenberg J, Moseley ME, Steinberg GK. Arterial spin-labeling mri can identify the presence and intensity of collateral perfusion in patients with moyamoya disease. Stroke. 2011;42(9):2485–91.
https://doi.org/10.1161/STROKEAHA.111.616466
12.
Alabousi M, Davenport MS. Use of intravenous gadolinium-based contrast media in patients with kidney disease and the risk of nephrogenic systemic fibrosis: radiology in training. Radiology. 2021;300(2):279–84.
https://doi.org/10.1148/radiol.2021210044
13.
Hu J, Li Y, Tong Y, Li Z, Chen J, Cao Y, et al. Moyamoya disease with initial ischemic or hemorrhagic attack shows different brain structural and functional features: a pilot study. Front Neurol. 2022;13.
https://doi.org/10.3389/fneur.2022.871421
14.
Zhang J, Xia C, Liu Y, Qian W, Peng W, Liu K, et al. Comparative study of mr mti-asl and dsc-pwi in evaluating cerebral hemodynamics of patients with moyamoya disease. Medicine. 2018;97(41):e12768.
https://doi.org/10.1097/MD.0000000000012768
15.
Qiao P-G, Han C, Zuo Z-W, Wang Y-T, Pfeuffer J, Duan L, et al. Clinical assessment of cerebral hemodynamics in moyamoya disease via multiple inversion time arterial spin labeling and dynamic susceptibility contrast-magnetic resonance imaging: a comparative study. J Neuroradiol. 2017;44(4):273–80.
https://doi.org/10.1016/j.neurad.2016.12.006
16.
Zaro-Weber O, Heiss W, Sobesky J. How reliable is pw-mri to detect elevated oxygen extraction fraciton (oef-pet) in stroke?Aktuelle Neurologie. 2009;36:P610.
17.
Ran YC, Zhu M, Zhang Y, Li TF, Cheng JL. Perfusion-weighted magnetic resonance imaging in the assessment of haemodynamics following stent angioplasty in patients with symptomatic middle cerebral artery plaque stenosis at the m1 segment. Exp Ther Med. 2017;14(3):1899–904.
https://doi.org/10.3892/etm.2017.4747
18.
Akiyama Y, Mikami T, Mikuni N. Deep learning-based approach for the diagnosis of moyamoya disease. J Stroke Cerebrovasc Dis. 2020;29(12):105322.
https://doi.org/10.1016/j.jstrokecerebrovasdis.2020.105322
19.
Gong E, Guo J, Liu J, Fan A, Pauly J, Zaharchuk G. Deep learning and multi-contrast-based denoising for low-snr arterial spin labeling (asl) mri: Medical Imaging 2020: image Processing. SPIE. 2020;11313:119–26.
20.
Wu F, Han C, Liu Y, Liu Z, Yang X, Wu Y, et al. Validation of choroidal anastomosis on high-resolution magnetic resonance imaging as an imaging biomarker in hemorrhagic moyamoya disease. Eur Radiol. 2021;31(7):4548–56.
https://doi.org/10.1007/s00330-020-07479-0
21.
Xu J, Rajah GB, Zhang H, Han C, Shen X, Li B, et al. Imaging features of adult moyamoya disease patients with anterior intracerebral hemorrhage based on high-resolution magnetic resonance imaging. J Cereb Blood Flow Metab. 2022:0271678X221111082.
© 2023 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2023
You do not currently have access to this content.